Business Insider
My Markets Watchlist
Markets Stocks

West Pharmaceutical Services Inc. Stock , WST

225.05 +0.84 +0.37%
03:59:59 PM BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Thursday 06/12/2025 the closing price of the West Pharmaceutical Services Inc. share was $225.05 on BTT. Compared to the opening price on Thursday 06/12/2025 on BTT of $223.23, this is a gain of 0.81%. West Pharmaceutical Services Inc.'s market capitalization is $13.15 B by 71.85 M shares outstanding.
Is West Pharmaceutical Services stock a Buy, Sell or Hold? West Pharmaceutical Services stock has received a consensus rating of buy. The average rating score is and is based on 5 buy ratings, 1 hold ratings, and 0 sell ratings.
What was the 52-week low for West Pharmaceutical Services stock? The low in the last 52 weeks of West Pharmaceutical Services stock was 187.50. According to the current price, West Pharmaceutical Services is 120.03% away from the 52-week low.
What was the 52-week high for West Pharmaceutical Services stock? The high in the last 52 weeks of West Pharmaceutical Services stock was 351.79. According to the current price, West Pharmaceutical Services is 63.97% away from the 52-week high.
What are analysts forecasts for West Pharmaceutical Services stock? The 6 analysts offering price forecasts for West Pharmaceutical Services have a median target of 400.17, with a high estimate of 536.00 and a low estimate of 275.00. The median estimate represents a 56.24 difference from the last price of 225.05.

West Pharmaceutical Services Stock Snapshot

211.25
Bid
100.00
Bid Size
236.40
Ask
100.00
Ask Size
6/12/2025
Date
3:59 PM
Time
20,682.00
Volume
224.21
Prev. Close
223.23
Open
16.10 B
Market Cap in USD
71.85 M
Number of Shares
71.85 M
Total Number of Shares
222.32
Day Low
226.54
Day High
225.05
187.50
52 Week Low
351.79
52 Week High
225.05
0.82
Dividend in USD
0.25
Dividend Yield
49.00
P/E Ratio
99.36
Free Float in %
6.69
EPS in USD
37.10
Book Value per Share in USD
8.87
Cash Flow per Share in USD

Historical Prices for West Pharmaceutical Services

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

West Pharmaceutical Services Analyst Data

Total Analysts: 6
Buy Ratings: 5 Neutral Ratings: 1 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 275.00 Median: 400.17 Highest: 536.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

West Pharmaceutical Services Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
03/18/25 Evercore
Maintained Buy $275
02/16/24 UBS
Maintained Hold $375
02/07/24 Jefferies & Company Inc.
Upgraded to Buy $536
10/27/23 Stephens Inc.
Maintained Buy $390
07/17/23 Stephens Inc.
Maintained Buy $420
06/16/23 Bank of America Merrill Lynch
Upgraded to Buy $405

West Pharmaceutical Services Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 2,960 3,133 3,333 3,508 3,651
Dividend 0.51 0.53 0.31 - -
Dividend Yield (in %) 0.22 % 0.23 % 0.14 % - -
EPS 6.29 7.11 8.12 8.55 9.18
P/E Ratio 36.19 32.00 28.04 26.64 24.80
EBIT 548 624 701 725 776
EBITDA 714 797 868 908 958
Net Profit 445 508 561 599 653
Net Profit Adjusted 451 510 556 600 -
Pre-Tax Profit 559 636 701 747 817
Pre-Tax Profit Reported 545 636 687 742 -
EPS (Non-GAAP) ex. SOE 6.29 7.11 8.12 8.55 9.18
EPS (GAAP) 6.06 7.08 7.81 8.72 -
Gross Income 998 1,098 1,209 1,264 1,295
Cash Flow from Investing -275 -300 - - -
Cash Flow from Operations 613 607 - - -
Cash Flow from Financing -61 -317 - - -
Cash Flow per Share 8.29 9.57 9.96 - -
Free Cash Flow 337 330 - - -
Free Cash Flow per Share 4.63 4.53 - - -
Book Value per Share 39.64 41.94 42.81 - -
Net Debt 33 24 2 - -
Research & Development Exp. 72 80 87 98 80
Capital Expenditure 275 250 220 - -
Selling, General & Admin. Exp. 372 395 409 434 423
Shareholder’s Equity 2,875 3,088 2,976 - -
Total Assets 3,911 4,198 - - -
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 12 12 12 12
Average Estimate - 1.521 USD 1.609 USD 6.291 USD 7.114 USD
Year Ago - 1.525 USD 1.868 USD 6.749 USD -
Publish Date - 7/24/2025 10/23/2025 - -
Revenue Estimates
No. of Analysts - 12 12 12 12
Average Estimate - 726 USD 757 USD 2,960 USD 3,133 USD
Year Ago - 702 USD 747 USD 2,893 USD -
Publish Date - 7/24/2025 10/23/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 2,892.70 2,951.10 2,885.50 2,830.70 2,146.70 1,843.60 1,718.00
Change of sales in % -1.98 2.27 1.94 31.86 16.44 7.31 7.36
Gross profit on sales 1,002.20 1,132.70 1,138.90 1,173.40 767.90 608.80 546.30
Gross profit on sales change in % -11.52 -0.54 -2.94 52.81 26.13 11.44 6.18
Operating income 594.60 710.90 763.50 758.70 419.00 297.20 254.80
Operating income change in % -16.36 -6.89 0.63 81.07 40.98 16.64 9.45
Income before tax 585.50 698.00 679.90 748.90 401.30 291.80 240.70
Income before tax change in % -16.12 2.66 -9.21 86.62 37.53 21.23 8.23
Income after tax 492.70 593.40 585.90 661.80 346.20 241.70 206.90
Income after tax change in % -16.97 1.28 -11.47 91.16 43.24 16.82 37.29

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 961.10 948.50 931.90 978.40 939.30 768.20 582.60
Long-term liabilities per share 5.68 3.76 5.57 5.18 5.89 5.76 4.03
Equity 2,682.30 2,881.00 2,684.90 2,335.40 1,854.50 1,573.20 1,396.30
Equity change in % -6.90 7.30 14.97 25.93 17.88 12.67 9.09
Balance sheet total 3,643.40 3,829.50 3,616.80 3,313.80 2,793.80 2,341.40 1,978.90
Balance sheet total change in % -4.86 5.88 9.14 18.61 19.32 18.32 6.23

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 39.25 39.19 38.07 37.10 28.32 24.45 22.79
P/E ratio (year end quote, basic EPS) 49.00 44.68 30.45 54.07 62.03 46.90 35.73
P/E ratio (year end quote, diluted EPS) 49.00 44.68 30.45 54.07 62.03 46.90 35.73
Dividend yield in % 0.25 0.22 0.31 0.15 0.23 0.41 0.59
Equity ratio in % 73.62 75.23 74.23 70.47 66.38 67.19 70.56
Debt ratio in % 26.38 24.77 25.77 29.53 33.62 32.81 29.44

West Pharmaceutical Services Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
BUTHMAN MARK A 05/05/2025 1,071.00 42,860.93 n/a Buy No
LAI GOLDMAN MYLA 05/05/2025 1,071.00 19,423.93 n/a Buy No
HAUGEN JANET BRUTSCHEA 05/05/2025 1,071.00 1,318.16 n/a Buy No
Joseph Molly 05/05/2025 1,071.00 2,884.44 n/a Buy No
Lockhart Stephen H 05/05/2025 1,071.00 2,708.41 n/a Buy No
Michels Douglas A 05/05/2025 1,071.00 45,171.05 n/a Buy No
Keller Deborah L 05/05/2025 1,071.00 10,656.72 n/a Buy No
Feehery William F 05/05/2025 1,071.00 31,363.13 n/a Buy No
FRIEL ROBERT F 05/05/2025 1,071.00 4,681.98 n/a Buy No
Green Eric Mark 02/17/2025 700.30 169,668.82 211.00 Sell No
Winters Chad 02/17/2025 27.73 1,363.03 211.00 Sell No
Witherspoon Charles 02/17/2025 23.49 1,295.36 211.00 Sell No
Favorite Annette F 02/17/2025 83.79 6,738.74 211.00 Sell No
Reiss-Clark Cindy 02/17/2025 83.18 5,047.33 211.00 Sell No
MacKay Kimberly Banks 02/17/2025 92.69 1,511.93 211.00 Sell No
Green Eric Mark 02/17/2025 2,460.99 170,369.12 211.00 Buy No
Winters Chad 02/17/2025 82.05 1,390.75 211.00 Buy No
Witherspoon Charles 02/17/2025 65.71 1,318.85 211.00 Buy No
Favorite Annette F 02/17/2025 246.16 6,822.53 211.00 Buy No
Reiss-Clark Cindy 02/17/2025 246.16 5,130.51 211.00 Buy No
MacKay Kimberly Banks 02/17/2025 246.16 1,604.63 211.00 Buy No
HAUGEN JANET BRUTSCHEA 12/15/2024 424.00 424.00 n/a Buy No
HAUGEN JANET BRUTSCHEA 12/15/2024 247.00 247.00 n/a Buy No
Witherspoon Charles 10/28/2024 225.00 1,253.14 310.40 Sell No
Witherspoon Charles 10/28/2024 478.00 1,478.14 310.40 Sell No

West Pharmaceutical Services Dividend Calendar

Date Name Dividend *yield Currency
2024 West Pharmaceutical Services Inc. 0.82 0.25 USD
2023 West Pharmaceutical Services Inc. 0.78 0.22 USD
2022 West Pharmaceutical Services Inc. 0.74 0.31 USD
2021 West Pharmaceutical Services Inc. 0.70 0.15 USD
2020 West Pharmaceutical Services Inc. 0.66 0.23 USD
2019 West Pharmaceutical Services Inc. 0.62 0.41 USD
2018 West Pharmaceutical Services Inc. 0.58 0.59 USD
2017 West Pharmaceutical Services Inc. 0.54 0.55 USD
2016 West Pharmaceutical Services Inc. 0.50 0.59 USD
2015 West Pharmaceutical Services Inc. 0.46 0.76 USD
2014 West Pharmaceutical Services Inc. 0.42 0.79 USD
2013 West Pharmaceutical Services Inc. 0.39 0.79 USD
2012 West Pharmaceutical Services Inc. 0.37 1.35 USD
2011 West Pharmaceutical Services Inc. 0.35 1.84 USD
2010 West Pharmaceutical Services Inc. 0.33 1.60 USD
2009 West Pharmaceutical Services Inc. 0.31 1.58 USD
*Yield of the Respective Date

West Pharmaceutical Services Calendar

Event Estimate Info Date
Earnings Report 1.521 USD Q2 2025 Earnings Release 07/24/2025
Earnings Report 1.609 USD Q3 2025 Earnings Release 10/23/2025
Earnings Report 1.711 USD Q4 2025 Earnings Release 02/12/2026
Earnings Report 1.536 USD Q1 2026 Earnings Release 04/23/2026

West Pharmaceutical Services Past Events

Event Actual EPS Info Date
Annual General Meeting 6.690 USD Annual General Meeting 05/06/2025
Earnings Report 1.230 USD Q1 2025 Earnings Release 04/24/2025
Earnings Report 1.780 USD Q4 2024 Earnings Release 02/13/2025
Earnings Report 1.850 USD Q3 2024 Earnings Release 10/24/2024
Earnings Report 1.510 USD Q2 2024 Earnings Release 07/25/2024
Earnings Report 1.550 USD Q1 2024 Earnings Release 04/25/2024
Annual General Meeting 7.880 USD Annual General Meeting 04/23/2024
Earnings Report 1.830 USD Q4 2023 Earnings Release 02/15/2024
Earnings Report 2.140 USD Q3 2023 Earnings Release 10/26/2023
Earnings Report 2.060 USD Q2 2023 Earnings Release 07/27/2023
Earnings Report 1.850 USD Q1 2023 Earnings Release 04/27/2023
Annual General Meeting 7.730 USD Annual General Meeting 04/25/2023
Earnings Report 1.360 USD Q4 2022 Earnings Release 02/16/2023
Earnings Report 1.590 USD Q3 2022 Earnings Release 10/27/2022
Earnings Report 2.480 USD Q2 2022 Earnings Release 07/28/2022
Annual General Meeting 8.670 USD Annual General Meeting 05/24/2022
Earnings Report 2.290 USD Q1 2022 Earnings Release 04/28/2022
Earnings Report 1.930 USD Q4 2021 Earnings Release 02/17/2022

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc. engages in the manufacture and marketing of pharmaceuticals, biologics, vaccines, and consumer healthcare products. It operates through the Proprietary Products and Contract-Manufactured Products segments. The Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA. .

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
2
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

West Pharmaceutical Services Management

Name Job
Eric Mark Green Chairman, President & Chief Executive Officer
Chad R. Winters Chief Accounting Officer & VP-Finance
Bernard J. Birkett Chief Financial Officer & Senior Vice President
Annette F. Favorite Chief Human Resources Officer & Senior VP
Shane Campbell Chief Proprietary Segment Officer & Senior VP
Kathy dePadua Chief Quality & Regulatory Officer, Senior VP
Deborah L. V. Keller Independent Director
Robert F. Friel Independent Director
Molly E. Joseph Independent Director
Janet Brutschea Haugen Independent Director
Mark A. Buthman Independent Director
William F. Feehery Independent Director
Douglas A. Michels Independent Director
Stephen H. Lockhart Independent Director
Myla P. Lai-Goldman Independent Director
Thomas W. Hofmann Independent Director
Paolo Pucci Lead Independent Director
Kimberly Banks MacKay Secretary, Senior Vice President & General Counsel
Rudy Poussot Senior VP-Strategy & Corporate Development
Quintin John Lai Vice President-Corporate Development & Strategy
Donald A. McMillan Vice President-Enterprise Business Systems